Document is current

Documents that mention this clinical trial

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
https://doi.org/10.1136/jitc-2020-001556

Documents that mention this clinical trial

Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post hoc analysis.
https://doi.org/10.1200/jco.2025.43.5_suppl.179

EMBARK post hoc analysis of sexual activity (SA) patient-reported outcome (PRO) measures.
https://doi.org/10.1200/jco.2024.42.4_suppl.313

Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol
https://doi.org/10.1136/bmjopen-2019-030218

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
https://doi.org/10.1136/jitc-2020-001556

Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.
https://doi.org/10.1200/jco.2024.42.4_suppl.15

EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL).
https://doi.org/10.1200/jco.2024.42.16_suppl.5084

A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design ^{(Pre-results)}
https://doi.org/10.1136/bmjopen-2020-046588

Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) plus leuprolide (combo): EMBARK post hoc analysis.
https://doi.org/10.1200/jco.2025.43.5_suppl.159

Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK.
https://doi.org/10.1200/jco.2024.42.4_suppl.156

EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL).
https://doi.org/10.1200/jco.2024.42.16_suppl.5005